<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>23(1)</volume><submitter>Al-Jedai A</submitter><journal>Cost effectiveness and resource allocation : C/E</journal><pagination>40</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12326838</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Pioneering SMA therapies for all types: survival gains, cost dynamics, and performance-based agreements.</pubmed_title><pmcid>PMC12326838</pmcid><pubmed_authors>Ojeil R</pubmed_authors><pubmed_authors>Al-Mudaiheem H</pubmed_authors><pubmed_authors>Awad N</pubmed_authors><pubmed_authors>AlSakran A</pubmed_authors><pubmed_authors>Almuhaizea MA</pubmed_authors><pubmed_authors>AlSamman A</pubmed_authors><pubmed_authors>Ghamdi F</pubmed_authors><pubmed_authors>Al-Jedai A</pubmed_authors><pubmed_authors>Bashiri FA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Pioneering SMA therapies for all types: survival gains, cost dynamics, and performance-based agreements.</name><description/><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Aug</publication><modification>2026-03-31T11:59:05.734Z</modification><creation>2025-09-01T03:08:29.462Z</creation></dates><accession>S-EPMC12326838</accession><cross_references><pubmed>40765022</pubmed><doi>10.1186/s12962-025-00647-3</doi></cross_references></HashMap>